ArticleAdvances in hematology2025
Comparison of Ideal vs. Actual Body Weight Dosing of Intravenous Immunoglobulins for Immune Thrombocytopenia: A Retrospective Analysis.
Article in Advances in hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparison of Ideal vs. Actual Body Weight Dosing of Intravenous Immunoglobulins for Immune Thrombocytopenia: A Retrospective Analysis.Advances in hematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Intravenous immunoglobulin (IVIG) is a weight-based therapy used to treat immune thrombocytopenia (ITP). Although pharmacokinetic data support the use of ideal body weight (IBW)-based dosing, clinical outcomes for this dosing strategy are lacking. Materials and Methods: This retrospective, multicenter chart review was conducted across five institutions compared clinical outcomes and costs for patients with ITP treated with IVIG dosed via actual body weight (ABW) or IBW. Data were collected from November 1, 2019 to April 10, 2024. The primary outcome was early platelet response, and secondary outcomes included length of stay (LOS) and increase in platelet count. Results: A total of 94 patients were included for analysis. No significant differences were noted between the ABW and IBW groups for early platelet response (59.1% vs. 47.2%, Conclusions: The utilization of IBW-based dosing of IVIG for ITP treatment was not associated with a change in early platelet response, LOS, or increase in platelet count compared with ABW-based dosing but was associated with cost savings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.